Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
Yan Liang, Bo Tu, Jun Yao, et al.
Cancer Research (2021) Vol. 81, Iss. 15, pp. 4054-4065
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Pancreatic cancer: Advances and challenges
Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1729-1754
Open Access | Times Cited: 576
Metabolic Reprogramming Induces Macrophage Polarization in the Tumor Microenvironment
Shilin Wang, Guohong Liu, Yirong Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 89
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Xiangdong Lv, Xuan Lu, Jin Cao, et al.
Science (2023) Vol. 381, Iss. 6662
Open Access | Times Cited: 51
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
Joel Encarnación-Rosado, Albert S.W. Sohn, Douglas E. Biancur, et al.
Nature Cancer (2023) Vol. 5, Iss. 1, pp. 85-99
Open Access | Times Cited: 45
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 30
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Eriocitrin attenuates sepsis-induced acute lung injury in mice by regulating MKP1/MAPK pathway mediated-glycolysis
Donghang Li, Yang Liu, Wei Wang, et al.
International Immunopharmacology (2023) Vol. 118, pp. 110021-110021
Closed Access | Times Cited: 25
Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy
Zhangyi Luo, Katherine M. Eichinger, Anju Zhang, et al.
Cancer Letters (2023) Vol. 575, pp. 216396-216396
Open Access | Times Cited: 25
Targeting Glucose Metabolism in Cancer Cells as an Approach to Overcoming Drug Resistance
Andrea Cunha, Patrícia Silva, Bruno Sarmento, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2610-2610
Open Access | Times Cited: 24
An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma
Zunyong Feng, Xuanbo Zhang, Jing Zhou, et al.
Nature Cancer (2023) Vol. 5, Iss. 1, pp. 30-46
Closed Access | Times Cited: 23
Emerging mechanisms and promising approaches in pancreatic cancer metabolism
Hao Wu, Mengdi Fu, Mengwei Wu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 8
Open Access | Times Cited: 13
Decoding the Intricate Landscape of Pancreatic Cancer: Insights into Tumor Biology, Microenvironment, and Therapeutic Interventions
Antonella Argentiero, Alessandro Andriano, Ingrid Catalina Caradonna, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2438-2438
Open Access | Times Cited: 5
Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions
Dhana Sekhar Reddy Bandi, Sujith Sarvesh, Batoul Farran, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 71-72, pp. 26-39
Closed Access | Times Cited: 12
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer
Pingping Hou, Xingdi Ma, Zecheng Yang, et al.
Genes & Development (2021) Vol. 35, Iss. 19-20, pp. 1327-1332
Open Access | Times Cited: 24
Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma
Zhao Liu, Hiromitsu Hayashi, Kazuki Matsumura, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 498-498
Open Access | Times Cited: 9
Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment
Arata Nishimoto
World Journal of Gastroenterology (2022) Vol. 28, Iss. 28, pp. 3637-3643
Open Access | Times Cited: 13
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer
Carlos Martínez-Pérez, Arran Turnbull, Charlene Kay, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 1, pp. 67-86
Open Access | Times Cited: 7
Conquering oncogenic KRAS and its bypass mechanisms
Pingping Hou, Yingshuang Wang
Theranostics (2022) Vol. 12, Iss. 13, pp. 5691-5709
Open Access | Times Cited: 12
WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer
Francesca Citron, I-Lin Ho, Chiara Balestrieri, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
CXCL12 secreted by pancreatic stellate cells accelerates gemcitabine resistance of pancreatic cancer by enhancing glycolytic reprogramming
Xiangyu Lu, Yilei Wu, Rui Cao, et al.
Animal Cells and Systems (2022) Vol. 26, Iss. 4, pp. 148-157
Open Access | Times Cited: 9
Synthetically Lethal Biomimetic Nutri-hijacker Hitchhikes and Reprograms KRAS Mutation-Driven Metabolic Addictions for Pancreatic Ductal Adenocarcinoma Treatment
Yukun Huang, Yu Chen, Songlei Zhou, et al.
ACS Nano (2023) Vol. 17, Iss. 14, pp. 14014-14031
Closed Access | Times Cited: 4
Metabolic signatures in pancreatic ductal adenocarcinoma: diagnostic and therapeutic implications
Ruining Gong, Yonglu Hu, Qian Yu, et al.
Journal of Pancreatology (2023) Vol. 6, Iss. 4, pp. 185-195
Open Access | Times Cited: 4
A Prognostic Survival Model of Pancreatic Adenocarcinoma Based on Metabolism-Related Gene Expression
Linying Xie, Hanying Huang, Tian Fang, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 7
TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4
Zhiwei He, Dijie Zheng, Fēi Li, et al.
Drug Resistance Updates (2024) Vol. 78, pp. 101171-101171
Closed Access | Times Cited: 1
Identification of Candidate Biomarker and Drug Targets for Improving Endometrial Cancer Racial Disparities
Pouya Javadian, Chao Xu, Virginie Sjoelund, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 7779-7779
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top